Patents by Inventor Sidney HOPPS

Sidney HOPPS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synergistic combination of oligonucleotides and chemotherapeutic for treating cancer
    Patent number: 11273172
    Abstract: Compositions and methods for treating cancers are provided which comprise administering a combination of antineoplastic agents, wherein the combination comprises protein kinase inhibitor, anthracycline, nucleoside analog, apoptosis-inducing molecular therapeutic or alkylating agent chemotherapeutics and one or more nucleic acid molecules capable of down-regulating expression of at least one splice variant of the IG20 gene, and wherein not all splice variants of the IG20 gene are down-regulated. Preferably, the splice variant of the IG20 gene is a MADD splice variant and the nucleic acid molecules are siRNA, shRNA and antisense oligonucleotides which comprise a nucleic acid sequence complementary to a nucleic acid sequence of exon 13L of the MADD splice variant or to an mRNA transcript of exon 13L of the MADD splice variant.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: March 15, 2022
    Assignees: The Board of Trustees of the University of Illinois, Jivana Biotechnology Inc.
    Inventors: Bellur Prabhakar, Sidney Hopps, Aditi Mathur, Fei Yue, Shikha Saini
  • SYNERGISTIC COMBINATION OF OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC FOR TREATING CANCER
    Publication number: 20200038426
    Abstract: Compositions and methods for treating cancers are provided which comprise administering a combination of antineoplastic agents, wherein the combination comprises protein kinase inhibitor, anthracycline, nucleoside analog, apoptosis-inducing molecular therapeutic or alkylating agent chemotherapeutics and one or more nucleic acid molecules capable of down-regulating expression of at least one splice variant of the IG20 gene, and wherein not all splice variants of the IG20 gene are down-regulated. Preferably, the splice variant of the IG20 gene is a MADD splice variant and the nucleic acid molecules are siRNA, shRNA and antisense oligonucleotides which comprise a nucleic acid sequence complementary to a nucleic acid sequence of exon 13L of the MADD splice variant or to an mRNA transcript of exon 13L of the MADD splice variant.
    Type: Application
    Filed: October 24, 2019
    Publication date: February 6, 2020
    Inventors: Bellur PRABHAKAR, Sidney HOPPS, Aditi MATHUR, Fei YUE, Shikha SAINI